OIE Collaborating Centre Reports
Activities in 2013
Title of Collaborating Centre:
Address of Collaborating Centre:
Collaborating Centre for Cell
Cultures
Via Bianchi 9, 25124, Brescia, Italy
Tel.:
+39-0302290248
Fax:
+39-0302290386
e-mail address:
substr@izsler.it
website:
Name of Director of Institute
(Responsible Official):
www.izsler.it
Prof. Stefano Cinotti
DVM, Professor
General Manager of IZSLER
Name (including Title and
Position) of Head of the
Collaborating Centre (formally
OIE Contact Point):
Dr. Maura Ferrari
Biologist
Head of Cell Culture Collaborating
Centre
Name (including Title and
Position) of writer of this report
(if different from above)
Annual reports of OIE Reference Centres, 2013
1
Cell Cultures
Summary of activities specifically related to the mandate of
OIE Collaborating Centres
ToR:
To provide services to the OIE, in particular within the region, in the designated
specialty, in support of the implementation of OIE policies and, where required, seek for
collaboration with OIE Reference Laboratories
ToR:
To identify and maintain existing expertise, in particular within its region
1.
Activities as a centre of research, expertise, standardisation and dissemination of
techniques within the remit of the mandate given by the OIE
Disease control
Epidemiology, surveillance, risk assessment, modelling
Training, capacity building
Zoonoses
Wildlife
Avian diseases
Aquatic animal diseases
Animal welfare
Diagnosis, biotechnology and laboratory
Veterinary medicinal products
Vaccines
Food safety
Feed safety
Other (Name the category: Cell cultures and their application for diagnosis, research, therapy,
production and new in vitro tests)
DIAGNOSIS, BIOTECHNOLOGY AND LABORATORY
Title of activity
Scope
Basic activity :
preparation,
amplification, control,
use and distribution of
the different types of
cell cultures obtained
from different sources
Maintain and increase the cell culture types to be used in the
different fields of Scientific Community for diagnosis, reasearch and
production of viruses from different species. Preparaton of reference
standards for controls of cells used in production of biologicals,
including vaccines. In 2013 the collection has resulted to be
composed by the following cell types:
Total No. of :
normal established cell lines
No. 224
tumour established cell lines
No. 247
hybridomas
No. 61
primary cell cultures
No. 65
animal Mesenchymal Stromal Cells
No. 26
Cell types: total number 623
Frozen cell vials: number 49,642
Cells that have been distributed: number 336
New Organizations
New Organizations that have requested cells to the OIE Collaborating
Centre: number 13 of which 8 national and 5 international
(Singapore, United Kingdom, France, Austria, Philippines);
In total 809 are the organizations that over the years have requested
cells to OIE Collaborating Centre. 675 of them are national; 121 are
of other countries
2
Annual reports of OIE Reference Centres, 2013
Cell Cultures
Other:
Title of activity
Scope
Detection of extraneous
agents by cell culture
isolation.
Testing of pharmaceutical products, viral vaccines, cells used for
vaccine production, mesenchymal stromal cells used for therapy,
cells used in virology laboratories in order to ensure their purity.
Validation of production
steps.
Evaluation of the efficacy of cleaning, disinfection and sterilization
procedures to inhibt virus replication. These tests are carried out
according to international guidelines
Quality controls
To ensure the characteristics, identity and purity of the the cell
cultures and based on testing methods to evaluate microbiological ,
mycoplasma and virus contamination. Oncogenic features are also
evaluated to ensure the safety of cells used for production of
vaccines and biologicals. All testing methods are in accordance to
European Pharmacopeia and performed according to quality
management system (ISO IEC 17025)
Preparation and
amplification of new cell
cultures
Research activity
To increase the cell culture collection with the aim to offer a wider
possibility of use (isolation of novel virus, development of new
serological tests, employment in new fields etc)
It was based on the studies made according to reasearch projects
approved with three main different strategies:
1) to improve knowlwdges on the therapeutic application of
Mesenchymal Stromal Cells in animals;
2) to develop new testing methods for virus detection and for
evaluation of other quality parameters;
3) to develop new in vitro tests to be used as alternative to in vivo
experiments conducted on animals.
ToR:
To propose or develop methods and procedures that facilitate harmonisation of
international standards and guidelines applicable to the designated specialty
2.
Proposal or development of any procedure that will facilitate harmonisation of
international regulations applicable to the surveillance and control of animal diseases,
food safety or animal welfare
Proposal title
Scope/Content
Applicable area
Development of
new testing
methods
To ensure the purity, safety, and
authentity of cell cultures, avoiding
to obtain not corrct results
regarding testing methods /
production / research carried out
with cells of no proper quality
parameters.
Surveillance and control of animal diseases
Reference
number of the
test:
02/308
Food safety
Animal welfare
Other
Testing methods developed in
2013:
Evaluation of cell cultures origin by
isoenzyme analysis (Authentikit™
Annual reports of OIE Reference Centres, 2013
3
Cell Cultures
Proposal title
Scope/Content
Applicable area
system, Innovative Chemistry)
02/309
Evaluation of the growth efficiency
of animal serum
02/310
Evaluation of the transformed
features of cell cultures by in vitro
test
02/311
Tumorigenicity of cell cultures by in
vivo test
02/328
Evaluation of mesenchymal stromal
cells differentiation capacity
toward adipocites
02/329
02/330
02/364
02/365
04/099
04/117
Evaluation of mesenchymal
stromal cells differentiation
capacity toward chondrocytes
Evaluation of mesenchymal stromal
cells differentiation capacity
towards osteoblasts
Evaluation of bacterial endotoxin
levels in biological and
pharmaceutical products
Biological evaluation of medical
devices by in vitro cytotoxicity
assay (MTT)
Detection of anti-PRRSV antibodies
by serum neutralization
05/26
Detection of adventitious viruses in
biological/pharmaceutical products
in cell culture
09/171
Detection of human
cytomegalovirus (HCMV) in
biological/pharmaceutical products
by PCR real-time (kit “Artus® CMV
RG PCR”)
09/172
Detection of Epstein-Barr virus
(EBV) in biological/pharmaceutical
products by PCR real-time (KIT
“Artus® EBV RG PCR”)
09/173
09/174
09/175
Detection of Hepatitis B virus (HBV)
in biological/pharmaceutical
products by PCR real-time (KIT
“Artus® HBV RG PCR”)
Detection of Hepatitis C virus (HCV)
in biological/pharmaceutical
products by RT-PCR real-time (KIT
“Artus® HCV RG RT-PCR”)
Detection of herpes simplex virus
(HSV) type 1 and type 2 in
biological/pharmaceutical products
by PCR real-time (KIT “Artus® HSV1/2 RG PCR”)
Detection of human
immunodeficiency virus (HIV) in
4
Annual reports of OIE Reference Centres, 2013
Cell Cultures
Proposal title
Scope/Content
09/177
cell culture and reagents by RT-PCR
real-time (KIT “Artus® HI Virus-1 RG
RT-PCR”)
09/189
Detection of human chondrocytes
molecular expression markers (link
protein and aggrecan) in
pharmaceutical products by PCR
09/190
Detection of Swine Classical fever
(SCF) in biological and
pharmaceutical products by PCR
Real-Time
09/191
Standardization
of the procedures
regarding all
steps involved in
cell culture field
Applicable area
Detection of swine parvovirus
(PPV) in biological and
pharmaceutical products by PCR
Real-Time
The flow chart of the cell culture
preparation, cultivation, control
and storage is approved by the
quality management system and it
allows to trace each step of the
process. The final product must
have high quality parameters and,
if possible, its range of application
must be evaluated (for instance
virus isolation, serological tests, in
vitro alternative methods, etc)
ToR:
To establish and maintain a network with other OIE Collaborating Centres designated
for the same specialty, and should the need arise, with Collaborating Centres in other
disciplines
ToR:
To carry out and/or coordinate scientific and technical studies in collaboration with
other centres, laboratories or organisations
3.
Did your Collaborating Centre maintain a network with other OIE Collaborating Centres
(CC), Reference Laboratories (RL), or organisations designated for the same specialty, to
coordinate scientific and technical studies?
Yes
Name of OIE CC/RL/other
organisation(s)
No
Location
Region of
networking Centre
Purpose
Centre de Recerca en
Sanitad Animal, CReSa,
campus UAB
Barcelona
(Spain)
Africa
Americas
Asia and Pacific
Europe
Middle East
to identify cell lines able to allow Porcine
reproductive and Respiratory Syndrome Virus
– PRRSV isolation from target tissues of
infected animals
OIE Reference Laboratory
for Avian influenza and
Newcastle disease
Padova,
Italy
Africa
Americas
Asia and Pacific
Europe
Middle East
to develope of expertise and standardization
of the cell culture for use in virology field; use
of cell lines as alternative to chichen embryos
for virus isolation and amplification
Annual reports of OIE Reference Centres, 2013
5
Cell Cultures
Name of OIE CC/RL/other
organisation(s)
4.
Region of
networking Centre
Location
Animal Health and
Veterinary Laboratories
Agency (AHVLA)
Surrey,
UK
OIE Reference Laboratory
for swine influenza
IZSLER
Parma,
Italy
Africa
Americas
Asia and Pacific
Europe
Middle East
to develope of expertise and standardization
of the cell culture for use in virology field; use
of cell lines as alternative to chichen embryos
for virus isolation and amplification
Africa
Americas
Asia and Pacific
Europe
Middle East
to develope of expertise and standardization
of the cell culture for use in virology field; use
of cell lines as alternative to chichen embryos
for virus isolation and amplification
Did your Collaborating Centre maintain a network with other OIE Collaborating Centres,
Reference laboratories, or organisations in other disciplines, to coordinate scientific and
technical studies?
Yes
Name of OIE CC/RL/other
organisation(s)
The National Centre for the
Replacement, Refinement
and Reduction of Animals in
Research (NC3Rs)
No
Location
London
United
Kingdom
Region of
networking
Centre
Purpose
Africa
Americas
Asia and Pacific
Europe
Middle East
Coooperation in the translation in
italian language of the ARRIVE
guidelines used to improve the
procedures of in vivo experiments;
their disclosure to Organizations
involved in this fields
National Reference Centre
for Classical and African
swine fever
IZS Perugia,
Italy
Africa
Americas
Asia and Pacific
Europe
Middle East
Cooperation in suggesting cell lines to
be used for virus isolation and
cultivation
Istituto Zooprofilattico
Sperimentale dell’Abruzzo e
del Molise: Reference
Centre for bluetongue virus
IZS Teramo,
Italy
Africa
Americas
Asia and Pacific
Europe
Middle East
Involved for field sera biobanking
toward bluetongue
The Roslin Institute,
University of Edinburgh,
(Prof. Tahar Ait-Ali)
Edinburgh
Africa
Americas
Asia and Pacific
Europe
Middle East
National Veterinary
Research Institute,
Department of Swine
Diseases OIE Reference
Laboratory for PRRS.
(Dr. Tomasz Stadejek)
University of NebraskaLincoln, School of Veterinary
and Biomedical Sciences
(Prof. Fernando Osorio)
6
Purpose
UK
Warsaw
Polond
Nebraska
Africa
Americas
Asia and Pacific
Europe
Middle East
Africa
Americas
Asia and Pacific
Europe
Middle East
Cost Action: viruses related to swine
respiratory disease with particular
reference to PRRS
Cooperation in pathogenetic studies on
PRRRSV virus infection in pigs
Annual reports of OIE Reference Centres, 2013
Cell Cultures
ToR:
To place expert consultants at the disposal of the OIE.
5.
Did your Collaborating Centre place expert consultants at the disposal of the OIE?
Yes
No
Name of expert
Kind of consultancy
Subject
Dr Maura Ferrari
Author of chapter
Author of Chapter of Molecular Diagnostics in
Laboratory Veterinary Practice (in
preparation)
Dr. Maura Ferrari
Co-author of chapter
Detection of Neutralizing Antibodies
in Pigs Inoculated with an Inactivated
Vaccine Against Porcine Circovirus Type
2 (PCV2)
ToR:
To provide, within the designated specialty, scientific and technical training to personnel
from OIE Member Countries
6.
Did your Collaborating Centre provide scientific and technical training, within the remit of
the mandate given by the OIE, to personnel from OIE Member Countries?
Yes
No
If the answer is yes, please provide the total number of trained persons for each of the following
categories:
a)
Technical visits: ................................................................ 2
b)
Seminars: .........................................................................
c)
Hands-on training courses: ..............................................
d)
Internships (>1 month): ...................................................
ToR:
To organise and participate in scientific meetings and other activities on behalf of the
OIE
7.
Did your Collaborating Centre organise or participate in the organisation of scientific
meetings on behalf of the OIE?
Yes
No
ToR:
To collect, process, analyse, publish and disseminate data and information relevant to
the designated specialty
8.
Publication and dissemination of any information within the remit of the mandate given by
the OIE that may be useful to Member Countries of the OIE
(Indicate in the appropriate box the number by category)
a)
Articles published in peer-reviewed journals: ................. 6
Renzi S, Riccò S, Dotti S, Sesso L, Grolli S, Cornali M, Carlin S, Patruno M, Cinotti S, and Ferrari M. (2013).
Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and
tendons: a clinical report. Res. Vet. Sci., 95 (1), 272-7.
Annual reports of OIE Reference Centres, 2013
7
Cell Cultures
Dotti S, Guadagnini G, Salvini F, Razzuoli E, Ferrari M, Alborali Gl, Amadori M. (2013). Time-course of antibody
and cell-mediated immune responses to porcine Reproductive and Respiratory syndrome virus under field
conditions. Res Vet Sci., 94, 510-517.
Riccò S, Renzi S, Delbue M, Conti V, Merli E, Ramoni R, Lucarelli E, Gnudi G, Ferrari M, Grolli S. (2013).
Allogenic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe
and effective in the therapy of superficial digital flexor tendonitis in the horse. Int J Immunopathol Pharmacol.
26, 61-68.
Petrini S, Paniccià M, Silenzi V, Ciuti F, Bresaola M, Fortunati M, Perugini G, De Mia GM, perugini G, Ferrari M,,
2013. Detection of neutralizing antibodies in pigs inoculated with an inactivated vaccine against porcine
Circovirus type 2 (PCV2). Trends in veterinary sciences: current aspects in veterinary morphophysiology,
biochemistry, animal production, food hygiene and clinical sciences. C. Boiti et al. (eds.), Trends in Veterinary
Sciences, DOI: 10.1007/978-3-642-36488-4_12, Springer-Verlag, 63-66.
Petrini S, Silenzi V, Manuali E, Paniccià M, Sensi M, Fortunati M, Feliziani F, Ferrari M, De Mia GM, 2013.
Association of the main viral pathogens with Porcine Respiratory Disease Complex (PRDC) in Central Italy.
Journal of Veterinary Diagnostic Investigation DOI 10.1007/s11259-013-9552-3, Vet Res Commun (2013)
37:251–257
Petrini S, Ramadori G, Villa R, Borghetti P, De Angelis E, Cantoni AM, Corradi A, Amici A, Ferrari M, 2013.
Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs.
doi:10.3390/vaccines1040463. Vaccines 2013, 1, 463-480.
b)
International conference presentations: ......................... 3
1) Time-course of antibody and cell-mediated immune responses to porcine reproductive and
respiratory syndrome virus under field conditions. 10th International Veterinary Immunology
Symposium (IVIS) : 28th August -1 St September 2013 Milan, Italy
An Italian Biobanking of Veterinary Resources at IZSLER. 7TH Epizone Annual Meeting : 1 - 4 October
2013, Bruxel, Belgium
2) Biobanking of animal Mesenchymal Stromal Cells and quality controls for a safe therapeutic
application.European Society Biopreservation and Biobanking (ESBB )Annual Meeting. 8 - 11 October
2013, Verona, Italy
3) Mesenchymal stromal cells (MSCs) alteration following in vitro amplification. Advances in In-Vitro
Cell and Tissue Culture and 5th Annual Quasi-Vivo® User Group Meeting. 21 - 22 May 2013,
Liverpool, United Kingdom
c)
National conference presentations: ................................ 5
1) Characterization of limbal cells and mesenchymal stromal cells (MSC) isolated from adipose tissue.
Annual Meeting ONLUS-AICC Stem Cell Research Italy International Society For Cellular Therapy. 2022 November 2013, Brescia, Italy.
2) The activity performed by Cell Culture Centre with mesenchymal stromal cells in toxicology field.
Italian Pltform on Alternative Methods (IPAM). Annual Meeting. Toxicology and stem cells.14
November 2013, Brescia, Italy.
3) Molecular changes associated with adaptation of avian influenza virus in embryonated chicken
eggs and in cell cultures. LXVII National Congress (Italian Society of Veterinary Sciences (S.I.S.Vet).
17-18-19 September 2013, Brescia, Italy.
4) Mesenchymal stromal cells: a promising tool in veterinary medicine.IV National Congress of Stem
Cell Research Society. 27-28-29 June 2013, Brescia, Italy.
5) Italian Reference Centre of Alternative Methods: activity and research for medical device. Meeting
on Alternative methods: 3Rs, research and regulatory aspects. 17-19 April 2013, Brescia, Italy
8
Annual reports of OIE Reference Centres, 2013
Cell Cultures
d)
Other: ............................................................................... 2
Two meetings organized by the Cell Culture Collaborating Centre are below reported
(www.izsler.it)
1) AICC–GISM 4th International Satellite Symposium. 20-22 November 2013, Brescia, Italy
2) Alternative methods: 3Rs, research and regulatory aspects. 17-19 April 2013, Brescia, Italy.
_______________
Annual reports of OIE Reference Centres, 2013
9